COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,722 Articles (22,913 medRxiv, 8,809 bioRxiv)

Most recent first Previous |  Page 3029: Articles 30281-30290  | Next

Classical drug digitoxin inhibits influenza cytokine storm, with implications for COVID-19 therapy.
Pollard, H. B., Pollard, B. S., Pollard, J. R.
10.1101/2020.04.09.034983 — Posted: 2020-04-11
A virus that has gone viral: Amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding and thus infectivity
Saha, P., Banerjee, A. K., Tripathi, P. P., Srivastava, A. K., Ray, U.
10.1101/2020.04.07.029132 — Posted: 2020-04-11
In-depth Bioinformatic Analyses of Human SARS-CoV-2, SARS-CoV, MERS-CoV, and Other Nidovirales Suggest Important Roles of Noncanonical Nucleic Acid Structures in Their Lifecycles
Bartas, M., Brazda, V., Bohalova, N., Cantara, A., Volna, A., Stachurova, T., Malachova, K., Jagelska, E. B., Porubiakova, O., Cerven, J., Pecinka, P.
10.1101/2020.04.09.031252 — Posted: 2020-04-11
Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: a computational biology approach
Lokman, S. M., Rasheduzzaman, M., Salauddin, A., Barua, R., Tanzina, A. Y., Rumi, M. H., Hossain, M. I., Siddiki, A. Z., Mannan, A., Hasan, M. M.
10.1101/2020.04.07.030924 — Posted: 2020-04-11
Integrative Network Biology Framework Elucidates Molecular Mechanisms of SARS-CoV-2 Pathogenesis
Kumar, N., Mishra, B., Mehmood, A., Athar, M., Mukhtar, M. S.
10.1101/2020.04.09.033910 — Posted: 2020-04-11
Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1
Li, Y., Wang, H., Tang, X., Ma, D., Du, C., Wang, Y., Pan, H., Zou, Q., Zheng, J., Xu, L., Farzan, M., Zhong, G.
10.1101/2020.04.10.032342 — Posted: 2020-04-11 Discussion: Onsite
De novo design of high-affinity antibody variable regions (scFv) against the SARS-CoV-2 spike protein
Boorla, V. S., Chowdhury, R., Maranas, C. D.
10.1101/2020.04.09.034868 — Posted: 2020-04-11
Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity
JIA, Y., Shen, G., Zhang, Y., Huang, K.-S., Ho, H.-Y., Hor, W.-S., Yang, C.-H., Li, C., Wang, W.-L.
10.1101/2020.04.09.034942 — Posted: 2020-04-11 Discussion: Onsite | Offsite
Comparative ACE2 variation and primate COVID-19 risk
Melin, A. D., Janiak, M. C., Marrone, F., Arora, P. S., Higham, J. P.
10.1101/2020.04.09.034967 — Posted: 2020-04-11 Discussion: Onsite
Projected early spread of COVID-19 in Africa
Pearson, C. A., Van Schalkwyk, C., Foss, A. M., O'Reilly, K. M., CMMID COVID-19 working group, , SACEMA 10 Modelling and Analysis Response Team, , Pulliam, J. R. C.
10.1101/2020.04.05.20054403 — Posted: 2020-04-10 Discussion: Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).